Non-small-cell lung cancer (NSCLC) is a common malignancy with a poor prognosis. Despite progress targeting oncogenic drivers, there are no therapies targeting tumor-suppressor loss. Smad4 is an established tumor suppressor in pancreatic and colon cancer; however, the consequences of Smad4 loss in lung cancer are largely unknown. We evaluated Smad4 expression in human NSCLC samples and examined Smad4 alterations in large NSCLC data sets and found that reduced Smad4 expression is common in human NSCLC and occurs through a variety of mechanisms, including mutation, homozygous deletion and heterozygous loss. We modeled Smad4 loss in lung cancer by deleting Smad4 in airway epithelial cells and found that Smad4 deletion both initiates and promotes lung tumor development. Interestingly, both Smad4 − / − mouse tumors and human NSCLC samples with reduced Smad4 expression demonstrated increased DNA damage, whereas Smad4 knockdown in lung cancer cells reduced DNA repair and increased apoptosis after DNA damage. In addition, Smad4-deficient NSCLC cells demonstrated increased sensitivity to both chemotherapeutics that inhibit DNA topoisomerase and drugs that block double-strand DNA break repair by non-homologous end joining. In sum, these studies establish Smad4 as a lung tumor suppressor and suggest that the defective DNA repair phenotype of Smad4-deficient tumors can be exploited by specific therapeutic strategies.
INTRODUCTION
Although over 175 000 cases of non-small-cell lung cancer (NSCLC) are diagnosed annually in the United States, the fiveyear survival rate remains less than 20%. 1 Despite advances in targeting oncogenic drivers, most NSCLC are not amenable to the currently available small-molecule inhibitors and there is a paucity of approaches targeting tumor-suppressor loss.
2 Smad4 mediates signaling of transforming growth factor β (TGFβ) and bone morphogenic protein ligands 3 and is a well-defined tumor suppressor in pancreatic and colon cancer. 4 Smad4 loss and mutation have also been described in NSCLC 5, 6 where they are associated with lymph node metastases, increased angiogenesis and more aggressive cellular behavior in vitro, 7, 8 although other consequences of Smad4 alterations in lung cancer are unknown.
In animal models, Smad4 deletion can initiate tumor formation in keratinized epithelial layers and can promote the development of tumors initiated by other oncogenic events. [9] [10] [11] [12] [13] [14] [15] [16] Smad4 loss increases proliferation secondary to loss of TGFβ-mediated growth suppression and also increases the proportion of well-differentiated tumors, presumably because Smad4 loss blocks TGFβ-driven epithelial-to-mesechymal transition. 10, 12, 14, 17 However, essentially nothing is known about whether Smad4 loss initiates or promotes lung tumor development in vivo or the characteristics of Smad4-deficient lung tumors.
TGFβ1 deletion increases genomic instability and sensitivity to ionizing radiation, 18, 19 and we previously reported that Smad4 deletion increases genomic instability in a mouse model of head and neck cancer. 11 These findings suggest that TGFβ signaling may regulate genomic stability through DNA repair. DNA repair is a complex process that requires detecting DNA damage and activating appropriate repair pathways. 20 Single-strand DNA damage is repaired through a combination of mismatch repair, base excision repair and nucleotide excision repair, whereas double-strand breaks (DSBs) are repaired by homologous recombination repair or nonhomologous end joining (NHEJ). 20 DSBs are sensed by ataxia telangiectasia mutated (ATM), which then activates homologous recombination repair 21, 22 and by Ku family proteins that then activate DNA-dependent protein kinase (DNA-PK) and repair through NHEJ. 23 Homologous recombination repair is more accurate as it relies on homologous sequences, whereas NHEJ has a lower fidelity and is responsible for the majority of tumorigenic chromosomal rearrangements. 23 In this study, we sought to evaluate the role of Smad4 loss in human lung cancer, to determine whether Smad4 is a lung tumor suppressor, and to assess DNA repair in Smad4-deficient lung cancer cells, with the ultimate goal of improving treatment strategies for Smad4-deficient tumors.
RESULTS

Reduced Smad4 expression is common in human NSCLC
Smad4 loss through a combination of mutation and homozygous deletion has been reported in 4-6% of NSCLC. 24, 25 However, other molecular events can also reduce Smad4 expression as the frequency of reduced Smad4 immunostaining far exceeds that of Smad4 mutation in most aerodigestive cancers. 4 We found reduced Smad4 immunostaining in 58% (98/168) of human NSCLC samples ( Figure 1a ) and observed that reduced Smad4 immunostaining was associated with reduced Smad4 mRNA expression (Figure 1b) , suggesting that Smad4 downregulation occurs pre-translationally. Consistent with data from The Cancer Genome Atlas, 25 we did not detect Smad4 promoter methylation by pyrosequencing (data not shown). When we assessed Smad4 copy number in NSCLC samples and paired non-malignant lung by quantitative PCR of genomic DNA, we observed reduced Smad4 copy number in 9% (9/95) of samples ( Figure 1c ) and all samples with Smad4 copy loss demonstrated reduced Smad4 immunostaining (Figure 1d ). In our data set, we did not detect associations between reduced Smad4 immunostaining, mRNA expression or copy loss and clinical or pathologic variables (data not shown). We also examined the frequency of Smad4 alterations in publically available NSCLC data sets using the cBioPortal website (http://www.cbioportal.org/public-portal/) and found that while Smad4 mutation or homozygous deletion were relatively rare, each occurring in o5% of NSCLC, heterozygous Smad4 loss was seen in 13% of lung squamous cell carcinomas and up to 47% of lung adenocarcinomas (Figure 1e ). Smad4 deletion initiates lung tumor formation and increases the size and malignant conversion of Kras-initiated lung tumors Because it was unknown whether Smad4 functions as a lung tumor suppressor, we created several novel NSCLC mouse models to directly evaluate the role of Smad4 loss in lung tumorigenesis. First, we induced Smad4 deletion in airway basal cells using either the K5CrePR* or K14CrePR transgene. 26, 27 Both constructs use a keratin promoter to direct expression of an RU486-inducible Cre recombinase-progesterone receptor (CrePR) fusion protein; recombination is limited to the lung by tracheal RU486 instillation. 28 This strategy induced tumor formation in 48% (11/23) -initiated lung tumors. (a) Tumor incidence, number and age in mice with the indicated genotypes. Animals were treated and monitored as described in Materials and Methods. Tumors were observed in 48% of animals with K5CrePR* (n = 13) or K14CrePR (n = 10) directed Smad4 deletion (hereafter referred to as Smad4 − / − animals). As Kras mutations are common in human lung cancer and can occur in conjunction with both Smad4 mutation and copy loss, 24, 25 we also assessed the effect of Smad4 deletion on Kras G12D -initiated lung tumor formation. Similar to what we previously observed, 29 
Kras
G12D activation directed by K5CrePR*-induced lung tumor formation in 48% (16/33) animals. To confirm Smad4 deletion, we extracted DNA from tumor and grossly normal lung and detected the recombinant Smad4 allele only in tumors (Supplementary Figure 1) , we also confirmed that tumors with Smad4 deletion also had reduced Smad4 immunostaining (Figure 2e , bottom panel). Although Smad4 deletion did not significantly increase tumor incidence or multiplicity (Figure 2a) , it almost doubled Kras G12D-initiated tumor size (Figure 2b ). An increase in tumor size was also seen when a single Smad4 allele was deleted ( Figure 2b ) consistent with Smad4 haploinsufficiency promoting tumor growth. We also observed that Kras.Smad4 Reduced Smad4 expression is associated with increased DNA damage Because TGFβ/Smad signaling regulates genomic stability, 11, 18 we assessed DNA damage in our mouse Smad4 − / − lung tumors using pH2AX immunostaining to mark DSB. Compared with Kras tumors, both Kras.Smad4
− / − and Smad4 − / − tumors demonstrated increased pH2AX staining (Figures 3a and b) . When we assessed whether human NSCLC, we found that reduced Smad4 immunostaining was associated with increased DSB (Figures 3c and e ). These data demonstrate that reduced Smad4 expression is associated with increased DNA damage in vivo and suggest genomic instability as a potential mechanism for tumor initiation by Smad4 deletion.
Reduced Smad4 expression reduces DNA repair and increases apoptosis after DNA damage Because Smad4-deficient tumors had increased DNA damage, we hypothesized that Smad4-deficient cells might exhibit reduced DNA repair. We stably knocked down Smad4 in Beas2B (SV40 T antigen immortalized) airway epithelial cells and purchased A549 lung adenocarcinoma cells with a zinc finger engineered Smad4 deletion (Sigma). Reduced Smad4 expression was confirmed at the mRNA and protein level (Supplementary Figure 2) . Both at baseline − / − cells also exhibited increased DNA damage by comet assay (Figure 4c) . Similarly, A549 Smad4 − / − cells also had increased DNA damage as measured by an increased number of nuclei with large number of pH2AX foci 12 h after an etoposide challenge (Figures 4d and e) , suggesting that Smad4-deficient cells have a reduced ability to resolve DNA damage.
We then tested whether increased DNA damage resulted in increased apoptosis or cell death in Smad4-deficient cells and found that Beas2B cells with Smad4 knockdown treated with camptothecin for 4 h demonstrated increased apoptosis as measured by Annexin V staining (Figure 5a ). A549 Smad4
− / − cells also exhibited increased apoptosis and cell death after 4 h treatment with camptothecin or etoposide when assayed either immediately after treatment or 24 h later (Figures 5b and c,  respectively) , suggesting that Smad4-deficient cells have increased apoptosis when faced with a genotoxic challenge. To assess whether apoptotic cells exhibited DNA damage, we simultaneously stained for both Annexin V to mark apoptotic cells and pH2AX to mark DSB. In both A549 and A549 Smad4
− / − cells, treatment with camptothecin or etoposide caused a large increase in the percentage of Annexin V-positive cells that also stained positive for pH2AX (Supplementary Figure 3) .
Reduced Smad4 expression increases sensitivity to DNA topoisomerase inhibitors and inhibitors of NEHJ Because reduced Smad4 expression increased apoptosis in response to DNA damage, we hypothesized that cells with low Smad4 expression would be more sensitive to DNA-damaging agents. We performed a series of cell viability assays in Beas2B cells with Smad4 knockdown and A549 Smad4 − / − cells and found that reduced Smad4 expression sensitizes to numerous DSBcausing drugs (gemcitabine, camptothecin, etoposide, doxorubicin (Figures 6a and b) . In contrast, reduced Smad4 expression had a more modest effect on sensitivity to alkylating-like agents (cisplatin) and DNA crosslinkers (mitomycin C), perhaps because the DNA adducts formed by these agents are predominantly intrastrand crosslinks not DSB. 30, 31 H1299 lung cancer cells with Smad4 knockdown also demonstrated increased sensitivity to both gemcitabine and etoposide in chemosensitivity assays (not shown). Corroborating these observations, in the Cancer Cell Line Encyclopedia, 32 low Smad4 expression correlates with increased sensitivity of NSCLC lines to the camptothecin derivatives, irinotecan and topotecan (Figures 6c and d) . As Smad4-deficient cells had defective DNA repair and increased apoptosis after DNA damage, we tested whether these cells were more sensitive to DNA repair inhibitors using a longterm proliferation assay and found that A549 Smad4
− / − cells were more sensitive to NU7441, a DNA-PK inhibitor (Figure 7a ), and to PI-103, a dual DNA-PK/mTOR (mammalian target of rapamycin) inhibitor (Figure 7b) , whereas H1299 cells with Smad4 knockdown were more sensitive to PI-103 (Figure 7c ). We also assessed activation of DNA repair pathways after DNA damage and found that A549 Smad4 − / − cells demonstrated reduced activation of both pDNA-PK and phosphorylated ataxia telangiectasia mutated (pATM) after etoposide treatment (Figure 8 ).
DISCUSSION
Reduced Smad4 expression is common in human NSCLC Reduced Smad4 expression was seen in 58% of our NSCLC samples ( Figure 1a ) and is likely a result of a combination of mutation, homozygous deletion and heterozygous loss. Our data are relatively consistent with genome-wide data sets demonstrating Smad4 alterations in 18-51% of NSCLC (Figure 1e ). Although the Cancer Genome Atlas data demonstrate heterozygous Smad4 loss in 13% of lung squamous cell carcinomas and 47% of lung adenocarcinomas, 24, 25 we detected Smad4 copy loss in only 9% of NSCLC. This difference is likely related to our conservative criteria for determining Smad4 copy loss with the CopyCaller v1.0 software: with less stringent criteria, we likely would have identified many more samples as having heterozygous Smad4 loss. Although Smad4 mutations have been previously associated with lymph node metastases, increased angiogenesis and more aggressive cellular behavior in vitro, 7, 8 we did not observe associations between reduced Smad4 expression and clinical or pathologic parameters. Reasons for the discrepancy between our data and a previous report 8 are not entirely clear. It could be that Smad4 loss is an early or tumor-initiating event and is not associated with more aggressive tumor behavior; however, even in pancreatic and colon cancer where Smad4 loss has been better characterized, relationships between Smad4 loss and more aggressive tumor behavior have not been consistently observed. 4 Targeting Smad4 deletion to airway basal cells initiates and promotes lung tumor formation One of our most significant findings is that Smad4 deletion both initiates spontaneous lung tumor formation and promotes the growth of Kras-initiated lung tumors. In other models, Smad4 deletion promotes tumor development initiated by Kras activation or phosphatase and tensin homolog deletion, [10] [11] [12] [13] [14] [15] [16] however, Smad4-initiated tumor formation has been previously described only in keratinized epithelial layers. [9] [10] [11] 17 In our model, targeting Smad4 deletion (with or without Kras activation) to keratinpositive airway basal cells produced predominantly adenomas and adenocarcinomas and~5% squamous cell carcinomas (not shown). This is consistent with our previous experience targeting oncogenic alterations to basal cells via a keratin promoter 29, 33 and demonstrates that airway basal cells can give rise to multiple tumor types in the same way that they can differentiate into multiple airway epithelial cell types. [34] [35] [36] We also observed that deletion of a single Smad4 allele increased both tumor size and malignant conversion (Figure 2) , consistent with the Smad4 haploinsufficiency seen in other models. 10, 11 Importantly, this suggests that the heterozygous Smad4 loss seen commonly in human NSCLC likely promotes tumor growth.
Smad4 loss increases DNA damage and reduces DNA repair Smad4 − / − murine lung tumors and human NSCLC with reduced Smad4 expression demonstrate increased DNA damage ( Figure 3 ) and Smad4-deficient cells have reduced DNA repair and reduced activation of DNA repair pathways after DNA damage (Figures 4 and  8) . Genomic instability provides a potential mechanism for tumor initiation by Smad4 deletion and was observed in our previous model where Smad4 deletion initiated tumor formation but was not seen in another model where Smad4 deletion did not initiate tumor formation. 11, 12 It is possible that reduced DNA repair in Smad4-deficient cells facilitates the accumulation of oncogenic mutations in vivo leading to tumor initiation after Smad4 loss.
The phenotype of Smad4-deficient cells reveals potential therapeutic strategies Our study demonstrates that Smad4 cells are more sensitive to certain DNA-damaging agents, specifically the DNA topoisomerase inhibitors, suggesting that Smad4-deficient tumors may be preferentially susceptible to similar treatments. Our observation that Smad4 knockdown sensitizes to DSB-causing drugs contrasts with previous reports demonstrating that Smad4 knockdown in colon or breast cancer cells decreases sensitivity to 5-fluorouracil (5-FU). 37, 38 This is likely related to the repair of 5-FU-related lesions by single-strand DNA repair pathways 39 and the repair of gemcitabine-, etoposide-and camptothecin-related DNA damage by DSB repair pathways. [40] [41] [42] [43] [44] Smad4-deficient cells have reduced activation of both pDNA-PK and pATM after DNA damage by etoposide ( Figure 8 ). Because there is substantial cross-talk between DSB repair by NHEJ and homologous recombination repair, 45, 46 additional studies will be required to mechanistically define the precise double-strand DNA repair defects present in Smad4-deficeint cells.
In summary, our study suggests that reduced Smad4 expression produces a potentially targetable tumor phenotype: one that will be more sensitive to treatment with DNA topoisomerase inhibitors and specific DNA repair inhibitors. It remains to be determined whether reduced Smad4 expression or Smad4 mutation correlates with increased responsiveness to the DNA topoisomerase inhibitors in human cancers. This would be highly relevant as most chemotherapy regimens for malignancies that frequently have Smad4 loss (NSCLC, head and neck cancer, colon cancer, pancreatic cancer) often do not include the agents to which Smad4-deficient cells are most sensitive. In addition, our findings pave the way for future studies using reduced Smad4 expression as a biomarker for selecting treatment approaches that exploit the defective DNA repair phenotype of Smad4-deficient cells.
MATERIALS AND METHODS
Analysis of human NSCLC samples
All studies were institutional review board approved. Human samples were obtained from three sources: the Oregon Health & Sciences University, Department of Pathology Tumor Bank (n = 37), the Colorado Lung SPORE Tissue Bank (n = 87) and a commercially available tissue microarray (n = 64, T8235724, lot A606098, Biochain, Hayward, CA, USA). Clinical and pathological data were extracted from the medical record or provided with the tissue array. Survival data were obtained by searching the social security death index database. Complete pathologic and demographic data are shown in Supplementary Table 1. Immunostaining for Smad4 (1:100 #7154, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was − / − cells using a cell viability assay. Data are expressed as the average fold decrease in EC50 (Smad4 deficient to control). All drugs were tested in at least two independent experiments. H1299 lung cancer cells with Smad4 knockdown also demonstrated increased sensitivity to gemcitabine and etoposide (data not shown). (c, d) Reduced Smad4 expression correlates with increased sensitivity (activity area) to camptothecin derivatives NSCLC cell lines in the Cancer Cell Line Encyclopedia. Although the association of reduced Smad4 expression and activity area was modest, it was confirmed by analysis of residuals.
performed as previously described. 29 Staining intensity was graded as preserved or reduced by two independent observers (SPM and SMH) and differences in immunostaining frequency between groups analyzed by χ 2 or Fisher's exact test. Reverse transcription-quantitative PCR with a Smad4 probe (Hs00232068, Life Technologies, Grand Island, NY, USA) was performed and analyzed by non-parametric methods (as previously described). 29 Smad4 copy number at exons 5 and 10 was assessed in tumor and matched normal lung DNA samples with Smad4 Copy Number Assays Hs01715545 and Hs02847956, an internal RNase P control and CopyCaller v1.0 software (Life Technologies) per the manufacture's recommendations (ΔCto 0.15, zo1.75). Double-strand DNA breaks were analyzed by immunostaining for pH2AX (1:100 #9718, Cell Signaling Technology, Danvers, MA, USA), quantified as the percent pH2AX-positive nuclei and differences compared with an unpaired t-test. − / − cells demonstrate reducted pDNA-PK and pATM after exposure to etoposide. Experiments were repeated at least twice.
conditional knock-in allele, K5Cre*PR transgene and K14CrePR transgene have been previously described. 26, 27, [47] [48] [49] Lung tumors were initiated with 500 μg tracheal RU486 at 4-6 weeks of age. Mice were euthanized between 12 and 18 months of age or if they lost 415% of their body weight; tumors were measured, enumerated, collected and then classified according to consensus criteria. 50 PCR for recombinant Kras and Smad4 alleles was performed as previously described. 51, 52 Smad4 and pH2AX immunostaining were performed as described above. Tumor cell size was analyzed by counting the number of cells in a × 40 field from hematoxylin and eosin-stained sections from at least five animals of each genotype. All images were acquired on a Nikon Eclipse 80i microscope with Nikon Elements Software (Nikon Instruments, Melville, NY, USA) and analyzed with ImageJ (http://rsbweb.nih.gov). Differences between groups were compared with one-way analysis of variance, unpaired t-test or Fisher's exact test as appropriate.
Generation and validation of cell lines
Beas2B (American Type Culture Collection, Manassas, VA, USA) were grown in BEGM (Lonza, Basel, Switzerland). A549 cells and A549 cells with Smad4 deletion (Sigma-Aldrich, St Louis, MO, USA) were grown in F12 supplemented with 10% fetal bovine serum and 2 mM L-glutamine. H1299 cells (American Type Culture Collection) were grown in RPMI supplemented with 10% fetal bovine serum. Cell lines with stable Smad4 knockdown were created by transfecting cells with pcPUR+U6 containing an anti-Smad4 small hairpin RNA 53 (kindly provided by Hideaki Ijichi, University of Tokyo, Japan) followed by puromycin selection; the pcPUR +U6 cassette (iGene Therapeutics, Tokyo, Japan) was used as a control. 
Comet assay
Beas2B cells (125 000) and A549 cells (100 000) were plated into 12-well plates and allowed to attach overnight. Beas2B cells were treated with camptothecin (5 μM for 24 h); A549 cells were treated with etoposide (100 μM for 4 h, assayed 24 h later). Cells were washed with phosphatebuffered saline (PBS) and removed from the plates by trypsinization, then 15 000 cells in 15 μl PBS were combined with 85 μl of agarose; 75 μl of this mixture was placed in each well of the OxiSelect Comet Assay Kit (Cell Biolabs, San Diego, CA, USA). Cells were then subject to alkaline electrophoresis per the manufacturer's instructions. Images were acquired on Nikon Eclipse 80i microscope and analyzed using CaspLab Comet Assay Software (http://casplab.com). Differences between groups were compared by unpaired t-test.
pH2AX immunofluorescence A549 Smad4
− / − cells (7500/well) were plated into glass chamber slides (BD Biosciences) and allowed to attach overnight. Cells were treated with etoposide (25 μM for 4 h) then harvested at various time points post treatment. Cells were washed with PBS, fixed with 4% paraformaldehyde (15 min at room temperature), washed with PBS, permeabilized with 100% ice-cold methanol and then washed again with PBS. After blocking (5% normal goat serum/1% bovine serum albumin/0.1% Triton X-100 for 1 h at room temperature), cells were stained overnight at 4°C with pH2AX antibody (1:400, Cell Signaling, in 5% normal goat serum/1% bovine serum albumin), rinsed with phosphate buffered saline with Tween then incubated with anti-rabbit Alexa Fluor 594 (1:500, Life Technologies) for 1 h at room temperature. Cells were then rinsed with phosphate buffered saline with Tween and mounted using DAPI Fluoromount-G (Southern Biotech, Birmingham, AL, USA). pH2AX immunostaining was quantified by counting at least 100 nuclei per treatment condition; differences were compared by χ 2 test.
Annexin V flow cytometry Beas2B cells with Smad4 knockdown were treated with 10 μM camptothecin for 4 h then harvested with TrypLE (Life Technologies) and assayed with the Dead Cell Apoptosis Kit (Life Technologies) per the manufacturer's instructions using a FC500 flow cytometer (BD Biosciences, San Jose, CA, USA). A549 Smad4 − / − cells were treated with camptothecin or etoposide, were harvested with TrypLE (Life Technologies) and then washed with cold PBS. Cells were assayed with the Fixable Viability Dye eFluor506, Annexin V PE Apoptosis Detection Kit and Anti-Human/mouse pH2AX (Ser139) PerCPeFluor 710 (all from eBioscience) per the manufacturer's protocol (http:// media.ebioscience.com/data/pdf/best-protocols/annexin-v-staining.pdf) using a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA).
Chemosensitivity assay
Cells were seeded at 1500/well (A549) or 3000/well (Beas2B and H1299) into 96-well plates and allowed to attach overnight. Cells were treated with chemotherapeutic agents (0.001-10 μM, depending on solubility) for 48-72 h then assayed using the CellTiter-Glo kit (Promega, Madison, WI, USA) per the manufacturer's instructions. Gemcitabine was from LC Laboratories (Wobern, MA, USA); doxorubicin, etoposide, mitomycin C, 5-fluorouracil, cisplatin and vinblastine were from Sigma; camptothecin was from Fisher Scientific (Pittsburg, PA, USA). Drug stocks were prepared in dimethyl sulfoxide (doxorubicin, etoposide, 5-fluorouracil, cisplatin, vinblastine, camptothecin) or PBS (gemcitabine, mitomycin C) and stored at − 80°C. Each drug was tested at least three times and IC50 determined using Prism software (GraphPad, La Jolla, CA, USA).
Clonogenic growth assay A549 and H1299 cells (100/well) were allowed to attach overnight then treated with NU7441 or PI-103 (Selleckchem.com, Houston, TX, USA) at the indicated concentrations for 17-22 days. Cells were then rinsed with PBS, stained with 0.5% crystal violet in 25% methanol, photographed and quantified using ImageJ as percent area covered. Differences between groups were compared by unpaired t-test.
